Description
Key facts
Cell type:U-2 OS,
Species or organism:Human,
Tissue:Bone,
Knockout validation:Next Generation Sequencing,Western blot,
Mutation description:Knockout achieved by CRISPR/Cas9 X = 2 bp deletion Frameshift = 97%,
Disease:Osteosarcoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-SUV39H2, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Next Generation Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
KMT1B also known as SUV39H2 is a lysine-specific histone methyltransferase enzyme located on chromosome 10q22.2. It catalyzes the methylation of histone H3 at lysine 9 (H3K9) which condenses chromatin into a more transcriptionally inactive state. KMT1B is approximately 50 kDa in mass and shows highest expression in testis and fetal tissues. It modifies chromatin structure to regulate gene expression patterns affecting cellular processes.
Biological function summary
This protein influences epigenetic constructs by being part of the transcriptional repressor complex. It is involved in gene silencing through the formation of heterochromatin an essential process for maintaining genome stability. KMT1B shares homology with SUV39H1 another histone methyltransferase and both cooperate in establishing heterochromatin markers.
Pathways
KMT1B participates in the transcriptional regulation pathway and intersects with pathways governing cell cycle control. It contributes to the E2F transcriptional repression pathway by interacting with retinoblastoma protein (pRB) which controls cell proliferation. This connection to pRB positions KMT1B as an influential factor in cell cycle checkpoints and progression.
KMT1B mutations have associations with neurodevelopmental disorders and some cancers. Its dysregulation can lead to anomalies in chromatin compaction affecting neurological development and potentially promoting oncogenesis. In cancer changes in KMT1B expression relate to abnormal cell growth often linked with parallel alterations in related enzymes like SUV39H1.
